A detailed history of China Universal Asset Management Co., Ltd. transactions in Amarin Corp Plcuk stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 76,959 shares of AMRN stock, worth $33,861. This represents 0.01% of its overall portfolio holdings.

Number of Shares
76,959
Previous 46,967 63.86%
Holding current value
$33,861
Previous $32,000 50.0%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$0.57 - $0.8 $17,095 - $23,993
29,992 Added 63.86%
76,959 $48,000
Q2 2024

Jul 19, 2024

SELL
$0.63 - $1.07 $17,142 - $29,115
-27,211 Reduced 36.68%
46,967 $32,000
Q1 2024

Apr 29, 2024

BUY
$0.82 - $1.35 $24,254 - $39,931
29,579 Added 66.32%
74,178 $66,000
Q4 2023

May 21, 2024

SELL
$0.66 - $0.91 $19,522 - $26,916
-29,579 Reduced 39.88%
44,599 $38,000
Q4 2023

Jan 23, 2024

BUY
$0.66 - $0.91 $22,918 - $31,599
34,725 Added 351.68%
44,599 $39,000
Q3 2023

May 21, 2024

BUY
$0.85 - $1.43 $4,110 - $6,915
4,836 Added 95.99%
9,874 $9,000
Q3 2023

Oct 30, 2023

BUY
$0.85 - $1.43 $4,110 - $6,915
4,836 Added 95.99%
9,874 $9,000
Q2 2023

May 21, 2024

SELL
$1.12 - $1.49 $152 - $202
-136 Reduced 2.63%
5,038 $5,000
Q2 2023

Jul 27, 2023

SELL
$1.12 - $1.49 $152 - $202
-136 Reduced 2.63%
5,038 $6,000
Q1 2023

May 21, 2024

BUY
$1.19 - $2.19 $1,304 - $2,400
1,096 Added 26.88%
5,174 $7,000
Q1 2023

Apr 27, 2023

BUY
$1.19 - $2.19 $1,304 - $2,400
1,096 Added 26.88%
5,174 $8,000
Q4 2022

May 21, 2024

SELL
$1.07 - $1.34 $75,007 - $93,934
-70,100 Reduced 94.5%
4,078 $4,000
Q4 2022

Jan 31, 2023

BUY
$1.07 - $1.34 $401 - $502
375 Added 10.13%
4,078 $5,000
Q3 2022

Oct 21, 2022

BUY
$1.09 - $1.67 $4,036 - $6,184
3,703 New
3,703 $4,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $177M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.